Eisai (ESALY) and Biogen (BIIB) announced that the European Medicines Agency has accepted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer’s disease with confirmed amyloid pathology, for review following a standard timeline.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
- Ionis confirms FDA to hold advisory committee meeting on tofersen NDA
- Biogen says FDA to convene advisory committee meeting for tofersen
- Donanemab CRL a ‘positive headline’ for Biogen’s Leqembi, says William Blair
- Eisai submits marketing authorization application for lecanemab in Japan